Green Approach Toward Triazole Forming Reactions for Developing Anticancer Drugs

• Published in: Current organic synthesis Vol. 21; no. 4; p. 380
• Main Authors: Rastogi, Shiva K, Ciliberto, Veronica C, Trevino, Monica Z, Campbell, Brooke A, Brittain, William J
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.01.2024
• Subjects: Alkynes - chemistry; Alkynes - pharmacology; Antineoplastic Agents - chemical synthesis; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Azides - chemistry; Cell Line, Tumor; Click Chemistry; Green Chemistry Technology - methods; Humans; Triazoles - chemical synthesis; Triazoles - chemistry; Triazoles - pharmacology; natural products; green approach; Click chemistry; anticancer; cytotoxicity; triazole
• ISSN: 1570-1794
• DOI: 10.2174/1570179420666230508125144

Compounds containing triazole have many significant applications in the dye and ink industry, corrosion inhibitors, polymers, and pharmaceutical industries. These compounds possess many antimicrobial, antioxidant, anticancer, antiviral, anti-HIV, antitubercular, and anticancer activities. Several synthetic methods have been reported for reducing time, minimizing synthetic steps, and utilizing less hazardous and toxic solvents and reagents to improve the yield of triazoles and their analogues synthesis. Among the improvement in methods, green approaches towards triazole forming biologically active compounds, especially anticancer compounds, would be very important for pharmaceutical industries as well as global research community. In this article, we have reviewed the last five years of green chemistry approaches on click reaction between alkyl azide and alkynes to install 1,2,3-triazole moiety in natural products and synthetic drug-like molecules, such as in colchicine, flavanone cardanol, bisphosphonates, thiabendazoles, piperazine, prostanoid, flavonoid, quinoxalines, C-azanucleoside, dibenzylamine, and aryl-azotriazole. The cytotoxicity of triazole hybrid analogues was evaluated against a panel of cancer cell lines, including multidrug-resistant cell lines.